GE HealthCare Technologies (US:GEHC)2025-10-29 10:25Financial Performance - Revenue for Q3 2025 was $5.1 billion, representing a 6% increase year-over-year, with organic revenue growth of 4% driven by EMEA and the U.S.[7] - Net income attributable to GE HealthCare was $446 million, down from $470 million in the prior year, resulting in a net income margin of 8.7%[7] - Diluted earnings per share (EPS) were $0.98, a decrease of $0.05 from the previous year, while adjusted EPS was $1.07, down $0.06 year-over-year[7] - Adjusted net income for Q3 2025 was $490 million, a decrease of 6% from $521 million in Q3 2024; for the nine months ended September 30, 2025, it increased by 3% to $1,441 million from $1,393 million in 2024[33] - The company reported a 18% increase in net income attributable to GE HealthCare for the nine months ended September 30, 2025, reaching $1,495 million compared to $1,272 million in 2024[33] Cash Flow and Investments - Cash flow from operating activities was $593 million, a decrease of $149 million year-over-year, and free cash flow was $483 million, down $168 million year-over-year[7] - Cash from operating activities for continuing operations decreased to $937 million in 2025 from $1,042 million in 2024, reflecting a decline of 10%[18] - Cash flows from investing activities for continuing operations totaled $(778) million in 2025, compared to $(674) million in 2024, indicating increased investment activity[18] - The company issued new debt amounting to $1,494 million in 2025, up from $994 million in 2024, reflecting a strategy to enhance liquidity[18] - Cash, cash equivalents, and restricted cash at the end of the period increased to $4,030 million in 2025 from $3,572 million in 2024[18] Revenue Segments - Imaging segment revenues were $2.349 billion, with a year-over-year growth of 5%, while Pharmaceutical Diagnostics saw a 20% increase in revenues[8] - Organic orders growth was 6%, with growth across all segments, and total company book-to-bill ratio was 1.06 times[6] - Total revenues for the nine months ended September 30, 2025, reached $14,927 million, a 4% increase from $14,353 million in 2024[26] - Organic revenue for the nine months ended September 30, 2025, was $14,792 million, representing a 3% growth compared to $14,349 million in 2024[26] - The company reported a 20% increase in PDx revenues for the three months ended September 30, 2025, reaching $749 million compared to $625 million in 2024[26] Guidance and Future Outlook - The company raised the lower end of its full-year 2025 adjusted EPS guidance range, now expecting adjusted EPS between $4.51 and $4.63[10] - Tariff impacts are estimated to affect adjusted EBIT by approximately $265 million and adjusted EPS by $0.45 for the full year[12] Operational Highlights - The company launched several new products, including CareIntellect for Perinatal and the AI-supported solution for radiation therapy workflow[11] - GE HealthCare announced the intent to acquire icometrix to enhance its neurology portfolio with brain MRI assessment solutions[11] - Non-operating benefit costs for Q3 2025 were $(75) million, compared to $(102) million in Q3 2024[33] - Restructuring costs for Q3 2025 were $31 million, up from $22 million in Q3 2024; for the nine months ended September 30, 2025, restructuring costs totaled $71 million, down from $90 million in 2024[33] Company Recognition and Contact Information - GE HealthCare is recognized as one of the 2025 Fortune World's Most Admired Companies™[49] - Investor Relations contact is Carolynne Borders, reachable at +1-631-662-4317[49] - Media contact is Jennifer Fox, reachable at +1-414-530-3027[49] - The company encourages following its social media channels for the latest news[49] - More information can be found on the official website: https://www.gehealthcare.com[49] Tax and Effective Rates - The effective tax rate for Q3 2025 was 27.8%, compared to 25.5% in Q3 2024; the adjusted effective tax rate was 21.8% for Q3 2025, up from 18.7% in Q3 2024[37]